Opus Genetics, Inc. (IRD): Operating Cash Flow
-$35.25M
Year ended 2025-12-31
-$40.67M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$35.25M | n/m | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | -$25.58M | n/m | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | -$1.11M | n/m | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $14.31M | n/m | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | -$19.37M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$6.80M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$3.59M | n/m | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | -$18.84M | n/m | 2020-02-21, From 2018-01-01 |
| 2017-12-31 | -$15.42M | n/m | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | -$13.23M | n/m | 2018-03-09, From 2016-01-01 |
| 2015-12-31 | -$17.35M | n/m | 2018-03-09, From 2015-01-01 |
| 2014-12-31 | -$11.04M | n/m | 2017-02-24, From 2014-01-01 |
| 2013-12-31 | -$7.98M | n/m | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | -$6.62M | n/m | 2014-03-21, From 2012-01-01 |
| 2011-12-31 | -$15.53M | n/m | 2013-03-22, From 2011-01-01 |
| 2010-12-31 | -$6.99M | n/m | 2012-03-16, From 2010-01-01 |
| 2009-12-31 | -$5.15M | n/a | 2012-03-16, From 2009-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$35.25M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$39.64M | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$63.50M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$407.0K | n/m |
| Palatin Technologies Inc (PTN) | 2026-06-30 | -$13.53M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$99.84M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$76.44M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | -$177.96M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$11.0K | n/m |
Compare IRD, ABUS, PYXS, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗